Learn More
PURPOSE This study evaluated the Argus II Retinal Prosthesis System (Second Sight Medical Products, Inc., Sylmar, CA) in blind subjects with severe outer retinal degeneration. DESIGN Single-arm, prospective, multicenter clinical trial. PARTICIPANTS Thirty subjects were enrolled in the United States and Europe between June 6, 2007, and August 11, 2009.(More)
The cross-correlation coefficient between neural spike trains is a commonly used tool in the study of neural interactions. Two well-known complications that arise in its interpretation are 1) modulations in the correlation coefficient may result solely from changes in the mean firing rate of the cells and 2) the mean firing rates of the neurons impose upper(More)
The Argus II Retinal Prosthesis System is the only commercially-approved treatment for severe to profound Retinitis Pigmentosa in the world. Over 10 years of research and development have gone into this device; it is now commercially available in the European Economic Area, Saudi Arabia, and in the United States. The Argus II System consists of an implant(More)
OBJECTIVE To demonstrate that an epiretinal prosthesis can produce patterned visual perception in patients blinded by photoreceptor degeneration who have no other treatment options. METHODS A totally blind subject with retinitis pigmentosa had a 16-electrode epiretinal prosthesis implanted. The implant is controlled wirelessly by an external computer or a(More)
BACKGROUND/AIMS To determine to what extent subjects implanted with the Argus II retinal prosthesis can improve performance compared with residual native vision in a spatial-motor task. METHODS High-contrast square stimuli (5.85 cm sides) were displayed in random locations on a 19″ (48.3 cm) touch screen monitor located 12″ (30.5 cm) in front of the(More)
BACKGROUND Retinal prosthesis systems (RPS) are a novel treatment for profound vision loss in outer retinal dystrophies. Ideal prostheses would offer stable, long-term retinal stimulation and reproducible spatial resolution in a portable form appropriate for daily life. METHODS We report a prospective, internally controlled, multicentre trial of the Argus(More)
OBJECTIVE To investigate the ability of 28 blind subjects implanted with a 60-electrode Argus II (Second Sight Medical Products Inc) retinal prosthesis system to detect the direction of a moving object. METHODS Blind subjects (bare light perception or worse in both eyes) with retinitis pigmentosa were implanted with the Argus II prosthesis as part of a(More)
PURPOSE Retinitis pigmentosa (RP) is a group of inherited retinal degenerations leading to blindness due to photoreceptor loss. Retinitis pigmentosa is a rare disease, affecting only approximately 100 000 people in the United States. There is no cure and no approved medical therapy to slow or reverse RP. The purpose of this clinical trial was to evaluate(More)
OBJECTIVE The purpose of this analysis was to compare observer-rated tasks in patients implanted with the Argus II Retinal Prosthesis System, when the device is ON versus OFF. METHODS The Functional Low-Vision Observer Rated Assessment (FLORA) instrument was administered to 26 blind patients implanted with the Argus II Retinal Prosthesis System at a mean(More)
Retinal prostheses, which restore partial vision to patients blinded by outer retinal degeneration, are currently in clinical trial. The Argus II retinal prosthesis system was recently awarded CE approval for commercial use in Europe. While retinal prosthesis users have achieved remarkable visual improvement to the point of reading letters and short(More)